Reckitt Benckiser Group (LON:RB) had its price objective lifted by Goldman Sachs Group from GBX 6,600 ($81.22) to GBX 7,000 ($86.14) in a report released on Thursday, Borsen Zeitung reports. They currently have a neutral rating on the stock.
A number of other research firms have also commented on RB. Berenberg Bank upped their price target on Reckitt Benckiser Group from GBX 8,000 ($98.45) to GBX 9,000 ($110.76) and gave the company a buy rating in a research report on Wednesday. Kepler Capital Markets upped their price target on Reckitt Benckiser Group from GBX 6,700 ($82.45) to GBX 7,250 ($89.22) and gave the company a buy rating in a research report on Monday, May 4th. Barclays upped their price target on Reckitt Benckiser Group from GBX 9,000 ($110.76) to GBX 9,400 ($115.68) and gave the company an overweight rating in a research report on Wednesday. JPMorgan Chase & Co. upped their price target on Reckitt Benckiser Group from GBX 8,000 ($98.45) to GBX 9,000 ($110.76) and gave the company an overweight rating in a research report on Wednesday. Finally, HSBC reiterated a buy rating and issued a GBX 8,300 ($102.14) price target on shares of Reckitt Benckiser Group in a research report on Monday, July 20th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and thirteen have given a buy rating to the company’s stock. Reckitt Benckiser Group has a consensus rating of Buy and a consensus price target of GBX 7,655.56 ($94.21).
Shares of RB stock opened at GBX 7,706 ($94.83) on Thursday. The firm has a market capitalization of $54.80 billion and a P/E ratio of -14.83. Reckitt Benckiser Group has a twelve month low of GBX 73.44 ($0.90) and a twelve month high of GBX 8,191.30 ($100.80). The company has a quick ratio of 0.40, a current ratio of 0.56 and a debt-to-equity ratio of 130.80. The stock’s fifty day simple moving average is GBX 7,441.20 and its 200 day simple moving average is GBX 6,629.16.
In related news, insider Nicandro Durante acquired 165 shares of the firm’s stock in a transaction on Wednesday, May 27th. The stock was purchased at an average cost of GBX 6,884 ($84.72) per share, with a total value of £11,358.60 ($13,978.10).
About Reckitt Benckiser Group
Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers acne treatment creams, facial washes, and cleansing pads; disinfection, hygiene, and first aid products; condoms, sex toys, and lubricants; heartburn and indigestion solutions; and cough and chest congestion, multi-symptom, and sinus remedies for adults and children under the Clearasil, Dettol, Durex, Gaviscon, and Mucinex brands.
See Also: Discover Your Risk Tolerance
Receive News & Ratings for Reckitt Benckiser Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser Group and related companies with MarketBeat.com's FREE daily email newsletter.